An interventional study of Simultaneous integrated boost to the tumor and positive mesorectal lymph nodes in Rectal Cancer and Radiation Oncology, sponsored by Claudia Schuurhuizen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Claudia Schuurhuizen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Rectal Neoplasms with a site in Netherlands — 21 open to participants now, 32 under way, 8 of them phase 3. Rectal Neoplasms · Netherlands.
Among the 74 studies in Rectal Neoplasms with a site in Netherlands, this one is the 51st largest by planned enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2026, is one of 16 with no phase, reaches primary completion later than 27 of the 31 other live ones, and was the 71st registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →21 of the 74 studies in Rectal Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:
Heike M.U. Peulen · Sites in Netherlands
Ages 18+
Maastricht Radiation Oncology · Sites in Netherlands
Ages 18+
GlaxoSmithKline · Sites in Netherlands, United States, Canada and 6 more countries
Ages 18+
Erasmus Medical Center · Sites in Netherlands
Ages 18+
Delcath Systems Inc. · Sites in Netherlands, United States, Czechia and 6 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 21 · Phase 3 21
First in 1993; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 108 across the 59 interventional studies, 133 across the 14 observational. Of the 30 that completed or were terminated, 3 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 74 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Claudia Schuurhuizen as lead sponsor.
Claudia Schuurhuizen has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Neoplasms with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02945566Phase 3University of BirminghamCan we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? | 2027-08 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT04927897Maastricht Radiation OncologyDETECT: Target Volume for Rectal Endoluminal Radiation Boosting | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 74 studies in Rectal Neoplasms with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective study is to evaluate if a higher radiation dose to the tumor can increase the organ preservation rate in non-locally advanced rectal cancer.
Rationale:
Organ preservation has emerged as a promising alternative to total mesorectal excision (TME) for non-locally advanced rectal cancer, aiming to reduce long-term functional impairments and improve quality of life. While magnetic resonance (MR)-guided radiotherapy boosts have shown potential in enhancing organ preservation rates, their high costs, prolonged treatment times and limited accessibility prevent widespread adoption. To address this gap in current treatment options, this study investigates a more accessible online adaptive boost strategy based on cone-beam computed tomography (CBCT) imaging, with the aim of expanding organ-preserving treatment options for rectal cancer patients.
Objective:
The primary objective of this study is to evaluate the organ preservation rate at two-year follow-up in patients with non-locally advanced rectal cancer. Secondary objectives include the assessment of clinical and pathological response rates, recurrence and survival outcomes, biological effects, treatment-related toxicities, bowel function, quality of life, tumor regression, CBCT-based workflow, and target and organ motion during treatment.
Study design:
This study is designed as a non-randomized, single arm, monocenter, phase II clinical trial.
Study population:
Patients (n=25) older than 18 years with non-locally advanced rectal cancer (defined as cT1-3N0-IM0) and a wish for organ preservation, who are referred for treatment.
Intervention (if applicable):
Addition of a simultaneous integrated boost (SIB) to the standard chemoradiotherapy (CRT) scheme of 2.0 Gy to the mesorectum. The radiotherapy scheme consists of 25 fractions, delivering 2.0 Gy per fraction to the mesorectum and 2.4 Gy per fraction to the tumor and positive mesorectal lymph nodes.
Main study parameters/endpoints:
This study aims to demonstrate that the investigated treatment approach results in an increased organ preservation rate of 70% at two year follow-up compared to historical data.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Preclinical data confirmed the feasibility of the investigated SIB-CRT approach, demonstrating limited and clinically acceptable increases in organ at risk doses compared to the standard CRT scheme, all remaining well within clinical constraints. Furthermore, current literature supports the safety of dose escalation CRT strategies for rectal cancer, reporting manageable acute toxicity profiles, with symptoms typically returning to baseline after treatment. Based on these data, the investigated SIB-CRT strategy is expected to result in only minimal additional toxicities compared to standard CRT therapy.
The additional burden for the participants includes five MRI scans (approximately five hours total), scheduled alongside routine visits to minimize inconvenience. Patients will also be asked to complete three questionnaires at five time points, requiring approximately two hours in total, and to provide one additional 20 mL blood sample during three routine blood withdrawals.
The principal investigators consider the additional potential risk and burden for patients in the study to be acceptable. This study aims to significantly improve organ preservation rates, offering a meaningful benefit to individual patients by potentially avoiding TME surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment arm, in which all participating patients will receive the simultaneous integrated boost (SIB)
Radiation: Simultaneous integrated boost to the tumor and positive mesorectal lymph nodes
Addition of a simultaneous integrated boost (SIB) to the standard chemoradiotherapy (CRT) scheme of 2.0 Gy to the mesorectum. The radiotherapy scheme consists of 25 fractions, delivering 2.0 Gy per fraction to the mesorectum and 2.4 Gy per fraction to the tumor and positive mesorectal lymph nodes.
Organ preservation
Organ preservation is considered unsuccessful if the rectum is surgically removed, a stoma is present, or a non-salvageable locoregional cancer recurrence is developed.
Time frame: During two-year follow-up
Rate of clinical complete response
Defined as the proportion of patients showing complete resolution of the tumor, assessed through endoscopy and MRI
Time frame: Assessed at the two response assessments (14-16 weeks and 26 weeks after the start of treatment)
Rate of pathological complete response
Evaluated in patients undergoing surgical resection who did not achieve cCR. pCR is defined as the absence of any residual tumor in surgical specimens, assessed via histopathological examination.
Time frame: During two-year follow-up
Local progression-free survival
Defined as the absence of tumor regrowth at or near the primary tumor site. Assessed through clinical evaluation and radiological imaging during the follow-up period.
Time frame: During two-year follow-up
Distant progression-free survival
Defined as the absence of distant metastasis or death from any cause. Monitored with regular imaging and clinical evaluations during the follow-up period.
Time frame: During three-year follow-up
Overall survival
Defined as the time from the start of treatment to death from any cause.
Time frame: During three-year follow-up
Biological effect of the treatment
Blood analyses to assess circulating tumor DNA (ctDNA) as a potential biomarker to predict treatment response.
Time frame: An additional 20 mL blood sample will be collected during scheduled blood withdrawal moments at three time points: (1) at baseline, (2) 2 weeks after start of treatment, and (3) 14-16 weeks after start of treatment.
Toxicities
Acute and late toxicities will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Both patient- and clinician-reported toxicity will be assessed during regular follow-up visits. Toxicities will be scored using the CTCAE scale, which ranges from Grade 0 (no toxicity) to Grade 5 (death), with higher grades indicating more severe adverse outcomes.
Time frame: During two-year follow-up
Bowel function
Evaluated using the low anterior resection syndrome (LARS) score, completed by the patient through a self-administered questionnaire. by a questionnaire which the patient fills in by themself. The total score ranges from 0 to 42 points, with higher scores indicating more severe symptoms. The following categories are used: 0-20 points: No LARS, 21-29 points: Minor LARS, 30-42 points: Major LARS
Time frame: Baseline and 3, 6, 12 and 24 months after start of treatment
Quality of Life (QoL)
Measured using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire, filled in by the patient. All of the scales and single-item measures range in score from 0 to 100. A high score for the functional scale and functional single-items represents a high or healthy level of functioning. A high score for the global health status/QoL scale represents a high QoL, whereas a high score for the symptom scale and single items represents a high level of symptomatology or problems.
Time frame: Baseline and 3, 6, 12 and 24 months after start of treatment
Quality of Life (QoL)
Measured using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CR29 questionnaire, filled in by the patient. All of the scales and single-item measures range in score from 0 to 100. A high score for the functional scale and functional single-items represents a high or healthy level of functioning, whereas a high score for the symptom scales and single-items represents a high level of symptomatology or problems.
Time frame: Baseline and 3, 6, 12 and 24 months after start of treatment
Tumor regression during treatment, monitored through weekly MRI scans
Weekly information to evaluate tumor regression during treatment. This includes five MRI scans in total, each requiring approximately one hour, including waiting time. Retrospectively, these scans will also be used to assess inter- and intrafractional motion of the target and OARs to investigate the potential for further margin reduction.
Time frame: Baseline, and treatment week 2, 3, 4 and 5
Target and organ intra- and interfraction motion
Daily CBCT scans acquired pre-, intra-, and post-treatment will be retrospectively analyzed to assess inter- and intrafractional motion of the target and OARs to investigate the potential for further margin reduction in millimeters.
Time frame: CBCT data is gathered daily as standard-of-care during the 5-week treatment
Feasibility of the CBCT-based SIB online adaptive workflow
Feasibility of the CBCT-based SIB online adaptive workflow including treatment time in minutes will be evaluated using treatment logs.
Time frame: During the 5-week treatment course
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Aug 2029, 42 months after the start.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 42 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.